SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 7, 2004--Gryphon Therapeutics (Gryphon) today announced that its technology for the construction of synthetic proteins is featured in the April issue of Scientific American. The Innovations section of the publication is devoted to Chemical Protein Synthesis (CPS), the technique Gryphon applies to the design and manufacture of its synthetic protein therapeutics. The article, entitled "Making Proteins Without DNA," discusses the history of the technology through the license of Gryphon's synthetic erythropoiesis protein (SEP) by Hoffman-LaRoche.
SEP, a 166 amino acid protein was built by total chemical synthesis using CPS and precision polymer technology. The end product is a precisely defined-novel macromolecule with comparable specific activity in vitro, but superior duration of action in animal models compared to human recombinant erythropoietin.
"We feel that the exposure of our technology to the public through this channel is key to a broad understanding of the power of our CPS platform," said Friedhelm Blobel, PhD - the President and CEO of Gryphon. "Using this technology, and our D-peptide therapeutics platform, we are well positioned to develop synthetic biotherapeutics for the major high-value markets."
Gryphon recently acquired world-wide non-exclusive rights to an mRNA-peptide display technology (sometimes referred to as PROfusion(TM) Technology) for the discovery of peptides with high affinity for selected targets which will bolster the Company's D-peptide therapeutics program. This technology will be used by Gryphon to develop peptides specific for therapeutic targets built using CPS. Additionally, Gryphon's wholly owned subsidiary, Cosmix molecular biologicals, GmbH, will use this as a tool to identify and improve peptide ligands for its customers.
About Gryphon Therapeutics
Gryphon Therapeutics, Inc. develops polymer-modified proteins made by total chemical synthesis, rather than biological methods. Gryphon's proprietary products combine chemically synthesized protein backbones with polymers to create potent biotherapeutics with superior pharmaceutical characteristics that access high value commercial markets. In the near term, the company intends to generate revenues through licensing performance-enhanced versions of known protein therapeutics, and in the long term intends to move its own products into the market place. Gryphon Therapeutics is a private company located in South San Francisco, California. For more information visit www.gryphonrx.com.
Gryphon Therapeutics Alexander R. Lussow, PhD, 650-952-7714 email@example.com